Copyright
©The Author(s) 2021.
World J Crit Care Med. Jan 9, 2021; 10(1): 22-34
Published online Jan 9, 2021. doi: 10.5492/wjccm.v10.i1.22
Published online Jan 9, 2021. doi: 10.5492/wjccm.v10.i1.22
Table 2 Percentage decrease in patients and vasopressor doses (survivors)
| Vasopressor drug, µg/kg/min | Pre CytoSorb®, therapy patient number (n), dose (median) | Post CytoSorb® Therapy, patient number (n), dose (median) | % Decrease in dose | P value (dose) |
| Norepinephrine | 21; 1 | 18; 0.45 | 43.3 | 0.160 |
| Epinephrine | 4; 0.055 | 1; 0.055 | 64.4 | - |
| Vasopressin | 9; 1.5 | 7; 1 | 15.4 | 0.816 |
- Citation: Paul R, Sathe P, Kumar RS, Prasad S, Aleem M, Sakhalvalkar P. Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb®) in patients with sepsis and septic shock. World J Crit Care Med 2021; 10(1): 22-34
- URL: https://www.wjgnet.com/2220-3141/full/v10/i1/22.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v10.i1.22